Jazz Pharmaceuticals

jazzpharma.com

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

201

Active

21

Phase 3

72

Total enrollment

30,002

Pipeline matrix

Showing 31 of 31 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Cannabidiol1
Zanidatamab7
Trastuzumab3
Gemcitabine4
Capecitabine4
Cisplatin3
Pembrolizumab2
Durvalumab2
Dordaviprone5
Vinorelbine2
Oxaliplatin2
Eribulin1
Tislelizumab1
5-Fluorouracil1
Xywav1
Dordaviprone (ONC201) + Placebo1
ONC2062
Lurbinectedin4
Paclitaxel2
Docetaxel1
Carboplatin1
Pertuzumab1
ONC206: Dose 11
ONC206: Dose 21
JZP35071
JZP0471
JZP8981
JZP8151
CBD-OS1
Epidiolex2
Epidiolex 100 mg/mL Oral Solution1

Next readouts

  • 2026-07
  • 2026-07
  • 2026-07-05
  • 2026-07-31
  • 2026-12-31
  • 2027-02
  • 2027-08-01
  • 2027-11-29
  • 2027-11-30
  • 2027-12-23

Top conditions

  • Narcolepsy15
  • Epilepsy14
  • Pain14
  • Multiple Sclerosis13
  • Acute Myeloid Leukemia10
  • Spasticity6
  • Fibromyalgia5
  • Acute Lymphoblastic Leukemia5

Frequently asked questions about Jazz Pharmaceuticals

How many clinical trials does Jazz Pharmaceuticals have on ClinicalTrials.gov?
Jazz Pharmaceuticals is listed as the lead sponsor on 201 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
How many of Jazz Pharmaceuticals's trials are in Phase 3?
72 of Jazz Pharmaceuticals's trials are in Phase 3, spread across 31 active drug programs.
What therapeutic areas does Jazz Pharmaceuticals focus on?
Jazz Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are Narcolepsy, Epilepsy, Pain, Multiple Sclerosis, Acute Myeloid Leukemia.
When are Jazz Pharmaceuticals's next clinical trial readouts?
Jazz Pharmaceuticals has 10 upcoming primary-completion readouts tracked here; the soonest is “Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting”, expected around 2026-07.